UroGen Pharma Ltd.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited; in thousands, except share and per share amounts)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $50,959 | $20,254 |
| Cost of revenue | 4,139 | 2,330 |
| Gross profit | 46,820 | 17,924 |
| Operating expenses: | ||
| Research and development expenses | 15,597 | 19,871 |
| Selling, general and administrative expenses | 51,486 | 34,967 |
| Operating loss | (20,263) | (36,914) |
| Financing on prepaid forward obligation | (4,506) | (4,583) |
| Interest expense on long-term debt | (4,185) | (4,068) |
| Interest and other income, net | 608 | 2,114 |
| Loss before income taxes | (28,346) | (43,451) |
| Income tax benefit (expense) | 4,772 | (392) |
| Net Loss | $(23,574) | $(43,843) |
| Statements of Comprehensive Loss | ||
| Net loss | $(23,574) | $(43,843) |
| Other comprehensive loss | ||
| Unrealized loss on investments | (11) | (42) |
| Comprehensive Loss | $(23,585) | $(43,885) |
| Net loss per ordinary share - basic and diluted | $(0.47) | $(0.92) |
| Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share | 50,182,758 | 47,422,119 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.